The therapeutic effects comparison of Parkinson′s syndrome in the early stage treated by dopamine agonist pramipexole and monoamine oxidase B inhibitor selegiline

doi:10.3877/cma.j.issn.2095-123X.2017.01.002

Abstract

Abstract:

Objective

To compare the clinical efficacy of dopamine agonists pramipexole and monoamine oxidase inhibitors B selegiline in the treatment of early Parkinson′s disease (PD).

Methods

Ninety patients with earlier stage of PD from May 2012 to October 2015 in the People′s Hospital of Xinjiang Uygur Autonomous Region were divided into control group (30 cases), pramipexole group (30 cases) and selegiline group (30 cases) according to random number table. The control group were given dopamine (62.5 mg/time of the initial dose, the dose was gradually increased to 125 mg/time according to the treatment effect, three times a day), pramipexole group and selegiline group were given pramipexole (1 mg/d) and selegiline (2.5 mg/d) respectively in the basis of dopamine. The unified PD rating scale (UPDRS) was adopted to evaluate patients, evaluation time respectively before and after treatment 1, 3, 6 months. At the same time, the adverse reactions were observed. All data were analyzed by SPSS 17.0.

Results

The total effective rates in the pramipexole group and selegiline group were 93.3% and 90.0%, respectively, which were significantly higher than those in the control group (70.0%, P<0.05). Before treatment, the UPDRS score of pramipexole group, selegiline group and control groups was not statistically significant (P>0.05). The pramipexole group and selegiline group patients UPDRS score decreased significantly, while the control group of patients UPDRS score decline is not obvious, the difference was statistically significant (P<0.05). For adverse reactions, PD patients pramipexole group of adverse reactions (60%) was higher than selegiline group (6.7%, P<0.05), but the symptoms can relieve itself.

Conclusion

The treatment of pramipexole and selegiline in PD is effective, safe. And, adverse effects were less in the selegiline group.

Key words: Pramipexole, Selegiline, Parkinson′s symptoms, Parkinson′s disease score, Clinical efficacy

Lijuan Yang, Xiaoshan Niu, Xiaoyan He, Jing Sha, Hongyan Li. The therapeutic effects comparison of Parkinson′s syndrome in the early stage treated by dopamine agonist pramipexole and monoamine oxidase B inhibitor selegiline[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2017, 07(01): 5-9.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2017.01.002

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2017/V07/I01/5

Figures/Tables 5

References 20

[1]	中华医学会神经病学分会帕金森病及运动障碍学组．中国帕金森病治疗指南(第三版)[J]．中华神经科杂志，2014(6)：428-433.
[2]	郝斌，周晓平. 帕金森病发病机制的研究[J]. 中国药物与临床，2004, 4(7): 525-527.
[3]	田明秀，张志清，解洪荣，等. 帕金森病发病机制的研究进展[J]. 中国老年学杂志，2012, 32(16): 3597-3601.
[4]	尹琳琳，朱兴族. 帕金森病的发病机制及其药物治疗研究进展[J]．国外医学：药学分册，2006, 33(2): 93-96.
[5]	尹世敏，王磊. 帕金森病运动症状的药物治疗[J]. 中国医药，2013, 8(1)：132-134
[6]	秦斌，曾湘豫. 帕金森病非痴呆和痴呆患者载脂蛋白E基因型分析[J]. 中华神经科杂志，1998, 31(3): 149-151.
[7]	叶民，董海蓉. 帕金森病的病因与发病机制研究进展[J]. 临床神经病学杂志，2002, 15(1): 57-59
[8]	王铭. 帕金森病的药物治疗[J]．中国医药指南，2014, 12(1): 48-49.
[9]	周泽仁. 帕金森病药物治疗的新进展[J]. 中国医药科学，2012, 2(12): 29-30.
[10]	Hauser RA,Zesiewicz TA. Advances in the pharmacologic management of early Parkinson disease[J]. The neurologist, 2007, 13(3): 126-132.
[11]	温洪波，张振馨，罗毅，等. 普拉克索治疗帕金森病的多中心，随机，双盲，溴隐亭对照临床疗效和安全性研究[J]. 中华神经科杂志，2006, 39(9): 604-608.
[12]	Eggert K,Öhlwein C,Kassubek J, et al. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole[J]. Clinical neuropharmacology, 2014, 37(4): 116-122.
[13]	Holloway RG,Shoulson I,Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial[J]. Archives of neurology, 2004, 61(7): 1044-1053.
[14]	杨新玲，贾丛康，张晨，等. 司来吉兰治疗帕金森病新进展[J]. 中国临床神经科学，2008, 16(4): 407-410.
[15]	Youdim MB,Collins GG,Sandler M. Monoamine oxidase: multiple forms and selective inhibitors[J]. Biochemical Journal, 1971, 121(3): 34-36
[16]	Magyar K. The pharmacology of selegiline[J]. Int Rev Neurobiol, 2011, 100: 65-84.
[17]	陈斐，管强，郑玉果，等. 司来吉兰联合复合多巴治疗帕金森病的有效性和安全性[J]. 中国神经免疫学和神经病学杂志，2013, 20(5): 352-356.
[18]	Palhagen S,Heinonen E,Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease[J]. Neurology, 2006, 66(8): 1200-1206.
[19]	武力勇，贾建平. 普拉克索的临床应用及安全性 [J]. 药物不良反应杂志，2007, 9(2): 77-80.
[20]	蒋雨平，蒋雯巍. 司来吉兰的临床研究进展及安全性[J]. 中国临床神经科学，2012, 20(4): 424-433.

组别	例数	显效	有效	无效	总有效率(%)
普拉克索组	30	20(66.7)	8(26.3)	2(6.7)	93.3
司来吉兰组	30	18(60.0)	9(30.0)	3(10.0)	90.0
对照组	30	10(33.3)	11(36.7)	9(30.0)	70.0

组别	例数	显效	有效	无效	总有效率(%)
普拉克索组	30	20(66.7)	8(26.3)	2(6.7)	93.3
司来吉兰组	30	18(60.0)	9(30.0)	3(10.0)	90.0
对照组	30	10(33.3)	11(36.7)	9(30.0)	70.0

组别	例数	用药前	1个月	3个月	6个月
普拉克索组	30	2.81±0.94	2.39±1.24^a	1.92±1.03^a	1.54±1.08^a
司来吉兰组	30	2.75±1.09	2.31±0.88^a	1.94±0.91^a	1.62±0.96^a
对照组	30	2.79±1.06	2.53±1.06	2.30±0.99	2.18±1.21

组别	例数	用药前	1个月	3个月	6个月
普拉克索组	30	2.81±0.94	2.39±1.24^a	1.92±1.03^a	1.54±1.08^a
司来吉兰组	30	2.75±1.09	2.31±0.88^a	1.94±0.91^a	1.62±0.96^a
对照组	30	2.79±1.06	2.53±1.06	2.30±0.99	2.18±1.21

组别	例数	用药前	1个月	3个月	6个月
普拉克索组	30	2.69±1.01	2.35±1.02^a	1.96±1.13^a	1.49±0.95^a
司来吉兰组	30	2.62±0.99	2.29±1.12^a	1.92±0.98^a	1.53±0.90^a
对照组	30	2.68±0.91	2.46±1.00	2.20±0.99	2.09±1.05

Please choose a citation manager

Content to export